An Artist Performs
Sahm Adrangi is a seasoned investor that has proven his mettle time and time again in the trading arena. He blazed a trail and made a name for himself rooting out and exposing corruption, scandal, and fraud in the Chinese business world, shorting multiple corrupt stocks to help build a strong portfolio. Sahm used this portfolio of $1 million to start his investment firm, Kerrisdale Capital. To date his firm is now handling over $150 million in investor capital.
While Sahm Adrangi has certainly built for himself a comfortable nest egg of capital, he isn’t spending his time sitting back, but helping to improve the market and making profitable trades all along the way. One of the ways Sahm’s firm has seen success is by narrowing their focus, sticking to only a few sectors of the finance world in order to specialize and make more efficient and effective trades.
Sahm Adrangi has narrowed his firm‘s focus on the biotechnology sector, an extremely profitable but fast moving market that requires substantial discipline and copious amounts of research in order to come out ahead. His firm, Kerrisdale makes it a point to publish and share research and development in this sector with the public and their investors. Biotechnology often has a lot of excellent innovations that come regularly to be traded publicly, making it a very profitable sector if one does the right research and trades with patience and tenacity.
Investors like Sahm Adrangi focus on the biotechnology sector because not only is it usually quite profitable for experienced traders, but also the money put into these sectors helps foster innovation in medicine, helping to improve lives all over the world by giving monetary incentive to those who innovate and develop new therapies for treatments against ailments like cancer.
Biotechnology promises to make some big strides in human potential, and with the financial backing provided by investors like Sahm, there is lots of room to move up. There are many exciting new developments in this sector that not only bring more money into the industry, but more hope for better therapies and technologies. Twitter